Skip to main content
PIQRAY header image

Take a proactive approach to managing select adverse reactions (ARs)

There are measures you can take before and during treatment to be prepared to manage your patients. Select from the options below to learn more about how to plan, monitor, and manage certain ARs.
Plan. Monitor. Manage

Please refer to the PIQRAY safety profile for additional ARs and the full Prescribing Information for additional monitoring and management guidance. The management plan of each patient should be based on the individual benefit/risk assessment.

Explore treatment considerations for select ARs

Select from the options below to learn more about monitoring considerations for serious and common ARs that may occur during treatment. As part of taking a proactive approach for managing your patients on PIQRAY, it's important to know what steps you can take before prescribing, recommendations for monitoring, and how ARs were managed in SOLAR-1. General guidelines for select ARs are summarized in the tabs below. For more information, please refer to the PIQRAY Prescribing Information.

Your Clinical Educator is available to answer any questions related to adverse reactions and dose modifications. They are dedicated to ensuring you have the right information so that you can optimize your patient's experience.


Important Safety Information

PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components.

Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms, including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia...


PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen...

References: 1. Piqray. Prescribing information. Novartis Pharmaceuticals Corp. 2. Data on file. Novartis Pharmaceuticals Corp; 2018. 3. Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med. 2018;379(21):2052-2062. 4. Boucher J, Kleinridders A, Kahn CR, et al. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):a009191. 5. Metz HE, Houghton AM. Insulin receptor substrate regulation of phosphoinositide 3-kinase. Clin Cancer Res. 2011;17(2):206-211. 6. Świderska E, Strycharz J, Wróblewski A, Szemraj J, Drzewoski J, Śliwińska A. Role of PI3K/AKT pathway in insulin-mediated glucose uptake. InTechOpen. 2018. DOI:10.5772/intechopen.80402. 7. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171-176.